Download PDF
Semin Neurol 2010; 30(5): 492-500
DOI: 10.1055/s-0030-1268860
© Thieme Medical Publishers

The Role of Antithrombotics in Secondary Stroke Prevention

Marc A. Lazzaro1 , Konark Malhotra1 , Yousef M. Mohammad1
  • 1Section of Cerebrovascular Disease and Neurocritical Care, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois
Further Information

Publication History

Publication Date:
04 January 2011 (online)

    Permissions and Reprints

ABSTRACT

Antithrombotic therapy plays a key role in secondary ischemic stroke prevention. A multitude of antithrombotic agents exist with varying pharmacologic, efficacy, and safety profiles. In this review, the authors discuss the mechanisms of antithrombotic therapy, summarize the data on commonly used agents, and introduce emerging antithrombotic medications.

KEYWORDS

Antiplatelets - anticoagulation - secondary stroke prevention - ischemic stroke

REFERENCES

  • 1 Grau A J, Weimar C, Buggle F et al.. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank.  Stroke. 2001;  32 (11) 2559-2566
    CrossrefPubMedGoogle Scholar
  • 2 Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project.  Stroke. 1994;  25 (2) 333-337
    CrossrefPubMedGoogle Scholar
  • 3 Messmore Jr H L, Jeske W P, Wehrmacher W et al.. Antiplatelet agents: current drugs and future trends.  Hematol Oncol Clin North Am. 2005;  19 (1) 87-117, vi vi
    CrossrefPubMedGoogle Scholar
  • 4 Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.  BMJ. 1994;  308 (6921) 81-106
    CrossrefPubMedGoogle Scholar
  • 5 Coull B M, Williams L S, Goldstein L B Joint Stroke Guideline Development Committee of the American Academy of Neurology et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association).  Stroke. 2002;  33 (7) 1934-1942
    CrossrefPubMedGoogle Scholar
  • 6 CAST (Chinese Acute Stroke Trial) Collaborative Group . CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke.  Lancet. 1997;  349 (9066) 1641-1649
    CrossrefPubMedGoogle Scholar
  • 7 International Stroke Trial Collaborative Group . The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke.  Lancet. 1997;  349 (9065) 1569-1581
    CrossrefPubMedGoogle Scholar
  • 8 van Kooten F, Ciabattoni G, Patrono C, Schmitz P I, van Gijn J, Koudstaal P J. Evidence for episodic platelet activation in acute ischemic stroke.  Stroke. 1994;  25 (2) 278-281
    CrossrefPubMedGoogle Scholar
  • 9 Patrono C, Roth G J. Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?.  Stroke. 1996;  27 (4) 756-760
    CrossrefPubMedGoogle Scholar
  • 10 Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.  J Neurol Neurosurg Psychiatry. 1991;  54 (12) 1044-1054
    CrossrefPubMedGoogle Scholar
  • 11 Albers G W, Tijssen J G. Antiplatelet therapy: new foundations for optimal treatment decisions.  Neurology. 1999;  53 (7, Suppl 4) S25-S31
    PubMedGoogle Scholar
  • 12 Sacco R L, Adams R, Albers G American Heart Association et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.  Stroke. 2006;  37 (2) 577-617
    CrossrefPubMedGoogle Scholar
  • 13 Ibanez B, Vilahur G, Badimon J J. Pharmacology of thienopyridines: rationale for dual pathway inhibition.  Eur Heart J. 2006;  8 (Suppl G) G3-G9
    CrossrefPubMedGoogle Scholar
  • 14 CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet. 1996;  348 (9038) 1329-1339
    CrossrefPubMedGoogle Scholar
  • 15 Holmes Jr D R, Dehmer G J, Kaul S, Leifer D, O'Gara P T, Stein C M. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.  J Am Coll Cardiol. 2010;  56 (4) 321-341
    CrossrefPubMedGoogle Scholar
  • 16 Hass W K, Easton J D, Adams Jr H P Ticlopidine Aspirin Stroke Study Group et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients.  N Engl J Med. 1989;  321 (8) 501-507
    CrossrefPubMedGoogle Scholar
  • 17 Gorelick P B, Richardson D, Kelly M African American Antiplatelet Stroke Prevention Study Investigators et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial.  JAMA. 2003;  289 (22) 2947-2957
    CrossrefPubMedGoogle Scholar
  • 18 Stoke Center. Cilostazol Stroke Prevention Study 2. 2010. Available at: http://www.strokecenter.org/trials/trialDetail.aspx?tid=952 Accessed August 1, 2010
    Google Scholar
  • 19 Diener H C, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.  J Neurol Sci. 1996;  143 (1-2) 1-13
    CrossrefPubMedGoogle Scholar
  • 20 Halkes P H, van Gijn J, Kappelle L J, Koudstaal P J, Algra A. ESPRIT Study Group . Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.  Lancet. 2006;  367 (9523) 1665-1673
    CrossrefPubMedGoogle Scholar
  • 21 Sacco R L, Diener H C, Yusuf S PRoFESS Study Group et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.  N Engl J Med. 2008;  359 (12) 1238-1251
    CrossrefPubMedGoogle Scholar
  • 22 Matías-Guiu J, Ferro J M, Alvarez-Sabín J TACIP Investigators et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.  Stroke. 2003;  34 (4) 840-848
    CrossrefPubMedGoogle Scholar
  • 23 Heeschen C, Hamm C W. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists.  Lancet. 2000;  355 (9201) 330-331
    CrossrefPubMedGoogle Scholar
  • 24 Topol E J, Easton D, Harrington R A Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.  Circulation. 2003;  108 (4) 399-406
    CrossrefPubMedGoogle Scholar
  • 25 Adams Jr H P, Effron M B, Torner J AbESTT-II Investigators et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II).  Stroke. 2008;  39 (1) 87-99
    CrossrefPubMedGoogle Scholar
  • 26 Chen Z M, Jiang L X, Chen Y P COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.  Lancet. 2005;  366 (9497) 1607-1621
    CrossrefPubMedGoogle Scholar
  • 27 Bhatt D L, Fox K A, Hacke W CHARISMA Investigators et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.  N Engl J Med. 2006;  354 (16) 1706-1717
    CrossrefPubMedGoogle Scholar
  • 28 Diener H C, Bogousslavsky J, Brass L M MATCH investigators et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.  Lancet. 2004;  364 (9431) 331-337
    CrossrefPubMedGoogle Scholar
  • 29 Kennedy J, Hill M D, Ryckborst K J, Eliasziw M, Demchuk A M, Buchan A M. FASTER Investigators . Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.  Lancet Neurol. 2007;  6 (11) 961-969
    CrossrefPubMedGoogle Scholar
  • 30 Stroke Center. Triple antiplatelets for reducing dependency after ischaemic stroke. 2010. Available at: http://www.strokecenter.org/trials/TrialDetail.aspx?tid=959 Accessed August 1, 2010
    Google Scholar
  • 31 Connolly S J, Pogue J, Hart R G ACTIVE Investigators et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.  N Engl J Med. 2009;  360 (20) 2066-2078
    CrossrefPubMedGoogle Scholar
  • 32 EAFT (European Atrial Fibrillation Trial) Study Group . Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.  Lancet. 1993;  342 (8882) 1255-1262
    PubMedGoogle Scholar
  • 33 The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group . A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin.  Ann Neurol. 1997;  42 (6) 857-865
    CrossrefPubMedGoogle Scholar
  • 34 Mohr J P, Thompson J L, Lazar R M Warfarin-Aspirin Recurrent Stroke Study Group et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.  N Engl J Med. 2001;  345 (20) 1444-1451
    CrossrefPubMedGoogle Scholar
  • 35 Chimowitz M I, Lynn M J, Howlett-Smith H Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.  N Engl J Med. 2005;  352 (13) 1305-1316
    CrossrefPubMedGoogle Scholar
  • 36 Halkes P H, van Gijn J, Kappelle L J, Koudstaal P J, Algra A. ESPRIT Study Group . Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.  Lancet Neurol. 2007;  6 (2) 115-124
    CrossrefPubMedGoogle Scholar
  • 37 Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.  JAMA. 1998;  279 (16) 1265-1272
    CrossrefPubMedGoogle Scholar
  • 38 Berge E, Abdelnoor M, Nakstad P H, Sandset P M. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.  Lancet. 2000;  355 (9211) 1205-1210
    CrossrefPubMedGoogle Scholar
  • 39 Diener H C, Ringelstein E B, von Kummer R Therapy of Patients With Acute Stroke (TOPAS) Investigators et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial.  Stroke. 2001;  32 (1) 22-29
    CrossrefPubMedGoogle Scholar
  • 40 Lee A Y, Levine M N, Baker R I Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349 (2) 146-153
    CrossrefPubMedGoogle Scholar
  • 41 Olsson S B. Executive Steering Committee of the SPORTIF III Investigators . Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.  Lancet. 2003;  362 (9397) 1691-1698
    CrossrefPubMedGoogle Scholar
  • 42 Connolly S J, Ezekowitz M D, Yusuf S RE-LY Steering Committee and Investigators et al. Dabigatran versus warfarin in patients with atrial fibrillation.  N Engl J Med. 2009;  361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 43 ROCKET AF Study Investigators . Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.  Am Heart J. 2010;  159 (3) 340-347, e1
    CrossrefPubMedGoogle Scholar

Marc A LazzaroM.D. 

Medical College of Wisconsin, Department of Neurology

9200 West Wisconsin Avenue, Wauwatosa, WI 53226

Email: mlazzaro2@gmail.com

      >